CA2438707A1 - Preparation contenant un mucopolysaccharide et son procede de production - Google Patents

Preparation contenant un mucopolysaccharide et son procede de production Download PDF

Info

Publication number
CA2438707A1
CA2438707A1 CA002438707A CA2438707A CA2438707A1 CA 2438707 A1 CA2438707 A1 CA 2438707A1 CA 002438707 A CA002438707 A CA 002438707A CA 2438707 A CA2438707 A CA 2438707A CA 2438707 A1 CA2438707 A1 CA 2438707A1
Authority
CA
Canada
Prior art keywords
mucopolysaccharide
formulation
absorption enhancer
formulation according
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438707A
Other languages
English (en)
Inventor
Akihiro Matsuura
Saori Mori
Kanji Takada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shimizu Pharmaceutical Co Ltd
Bioserentach Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2438707A1 publication Critical patent/CA2438707A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Abstract

On produit une préparation entérique à administrer par voie orale, contenant un mucopolysaccharide, en utilisant un agent augmentant l'absorption pour le mucopolysaccharide, comprenant un acide gras possédant 6 à 14 atomes de carbone ou un sel, un ester ou un dérivé amide de celui-ci ; de l'acide carboxylique stéroïde, ou un sel, un ester ou un dérivé amide de celui-ci ; et un acide polybasique aliphatique, ou un sel, un ester ou un dérivé amide de celui-ci ; ou des mélanges de ceux-ci. Ledit mucopolysaccharide a seulement été administré dans des préparations à injecter et la concentration effective dans le sang de mucopolysaccharide n'a pas été obtenue par administration orale.
CA002438707A 2001-02-16 2002-02-15 Preparation contenant un mucopolysaccharide et son procede de production Abandoned CA2438707A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001040661 2001-02-16
JP2001-40661 2001-02-16
JP2001299632 2001-09-28
JP2001-299632 2001-09-28
PCT/JP2002/001299 WO2002064148A2 (fr) 2001-02-16 2002-02-15 Preparation contenant un mucopolysaccharide et son procede de production

Publications (1)

Publication Number Publication Date
CA2438707A1 true CA2438707A1 (fr) 2002-08-22

Family

ID=26609566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438707A Abandoned CA2438707A1 (fr) 2001-02-16 2002-02-15 Preparation contenant un mucopolysaccharide et son procede de production

Country Status (5)

Country Link
EP (1) EP1390048A2 (fr)
JP (1) JP2004525110A (fr)
KR (1) KR20040018333A (fr)
CA (1) CA2438707A1 (fr)
WO (1) WO2002064148A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
CA2723541A1 (fr) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions de peptides et leurs procedes de preparation
JP4630931B2 (ja) * 2009-03-10 2011-02-09 有限会社エヌアール・ラボラトリー 消化管溶性剤型
WO2011120033A1 (fr) 2010-03-26 2011-09-29 Merrion Research Iii Limited Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
KR101005981B1 (ko) * 2010-08-13 2011-01-05 이흥재 핸들부를 앞뒤로 왕복시키는 동작으로 전륜을 구동하는 자전거
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
BR112013014940A2 (pt) * 2010-12-15 2016-09-13 Merrion Reserarch Iii Ltd composições farmacêuticas de inibidores de fator xa seletivos para administração oral
BR112013017169A2 (pt) 2011-01-07 2016-10-04 Merrion Res Iii Ltd composições farmacêuticas de ferro para administração oral
EP2834635A4 (fr) * 2012-04-03 2015-09-02 Smiths Medical Asd Inc Compositions d'agents de charge d'héparine et procédés associés
ITMI20130682A1 (it) * 2013-04-24 2014-10-25 Giuliani Spa Forme di dosaggio per la somministrazione orale di sostanze attive
EP3250191B1 (fr) 2015-01-29 2024-01-17 Novo Nordisk A/S Comprimés contenant un agoniste de glp-1 et revêtement gastro-résistant
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US7097851B1 (en) * 1998-11-27 2006-08-29 Kanji Takada Oral formulation for gastrointestinal drug delivery
WO2000050012A1 (fr) * 1999-02-22 2000-08-31 Elan Corporation, Plc Dose orale solide contenant un agent de potentialisation
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin

Also Published As

Publication number Publication date
WO2002064148A3 (fr) 2002-11-21
KR20040018333A (ko) 2004-03-03
WO2002064148A2 (fr) 2002-08-22
JP2004525110A (ja) 2004-08-19
EP1390048A2 (fr) 2004-02-25

Similar Documents

Publication Publication Date Title
CA2438707A1 (fr) Preparation contenant un mucopolysaccharide et son procede de production
US20200000726A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
EP0667148B1 (fr) Preparation pharmaceutique perorale liberable dans le tube digestif inferieur
US20190125711A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
ES2649063T3 (es) Formulaciones farmacéuticas que contienen rifaximina, procedimientos para su obtención y método de tratamiento de la enfermedad intestinal
KR20040037026A (ko) 심장병 및 순환성 질병을 치료하고 예방하기 위한 하루1회 요법용 제어방출형 경구 약제학적 조성물
EP1622601B1 (fr) Compositions pharmaceutiques
TWI483748B (zh) 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
JP2005516020A (ja) ゼロ次持続放出剤形およびその製造方法
JP2008525335A (ja) 経口投与できる固体の放出改変型医薬投与形
TWI343262B (en) Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US9284341B2 (en) Rapidly dissolving pharmaceutical composition
WO2007037259A1 (fr) Préparation pour impulsion ayant de meilleures propriétés de désintégration in vivo
CN112451531B (zh) 一种阿司匹林和利伐沙班复方制剂及其制备方法
DK2679216T3 (en) Pharmaceutical form for modified release of betahistine
EA011215B1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту, плавающая капсула
CA2881726A1 (fr) Compositions de nitrate d'aminoalkyle a diffusion prolongee
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
AU2002232203A1 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
JP3122478B2 (ja) 下部消化管放出型経口製剤
JPWO2002060448A1 (ja) 医薬組成物
US20220071913A1 (en) Granule, preparation containing the granule, production method of the granule, and production method of preparation containing the granule
US20230263901A1 (en) Mucus adhesion drug delivery
CN103505461A (zh) 一种乐卡地平与贝那普利的固体药物组合物
JP2004339083A (ja) ムコ多糖類製剤

Legal Events

Date Code Title Description
FZDE Dead